Black Rock Inc. Iveric Bio, Inc. Transaction History

Black Rock Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$26.24 - $39.63 $17.3 Million - $26.2 Million	661,051 Added 6.53%	10,789,526 $424 Million
Q1 2023 May 12, 2023	BUY	$18.67 - $24.56 $7.04 Million - $9.27 Million	377,320 Added 3.87%	10,128,475 $246 Million
Q4 2022 Feb 13, 2023	BUY	$17.24 - $23.95 $28 Million - $38.9 Million	1,626,091 Added 20.01%	9,751,155 $209 Million
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $709,380 - $1.4 Million	75,466 Added 0.94%	8,125,064 $146 Million
Q2 2022 Aug 12, 2022	SELL	$9.12 - $18.9 $3.5 Million - $7.25 Million	-383,656 Reduced 4.55%	8,049,598 $77.4 Million
Q1 2022 May 12, 2022	SELL	$12.15 - $16.83 $502,815 - $696,492	-41,384 Reduced 0.49%	8,433,254 $142 Million
Q4 2021 Feb 10, 2022	BUY	$13.83 - $18.78 $9.81 Million - $13.3 Million	709,143 Added 9.13%	8,474,638 $142 Million
Q3 2021 Nov 09, 2021	BUY	$7.07 - $17.5 $7.19 Million - $17.8 Million	1,016,533 Added 15.06%	7,765,495 $126 Million
Q2 2021 Aug 11, 2021	BUY	$5.69 - $7.17 $38.4 Million - $48.4 Million	6,748,962 New	6,748,962 $42.6 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.